Belgium· BE-AMP-SAM516577-00
Vosevi 400 mg - 100 mg - 100 mg
A sofosbuvir, velpatasvir and voxilaprevir product containing velpatasvir, registered in Belgium by Gilead Sciences Ireland UC. The same ATC class is registered in 13 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Sofosbuvir, velpatasvir and voxilaprevir is registered in 13 of 19 countries.
Countries holding a registration under ATC J05AP56 (sofosbuvir, velpatasvir and voxilaprevir), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 10 of them publish a price we can compare per daily dose
Sofosbuvir, velpatasvir and voxilaprevir · ATC J05AP56
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of sofosbuvir, velpatasvir and voxilaprevir costs, country by country.
Normalised to the WHO defined daily dose (0.4 g), the median price runs from $447.39 in Switzerland to $1097.10 in Italy — a ×2.5 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Sofosbuvir, velpatasvir and voxilaprevir · price per daily dose (0.4 g)
USD · FX 28 Sept 2026
- IT Italy$1097.10
- CH Switzerland$447.39
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Velpatasvir
- Manufacturer
- Gilead Sciences Ireland UC
- Country
- Belgium (BE)
- ATC code
- J05AP56
- ATC class
- Sofosbuvir, velpatasvir and voxilaprevir
- Defined daily dose
- 0.4 g, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 3
- be_apb3641750
- be_apb7722655
- be_apb3919321
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under J05AP56
Sofosbuvir, velpatasvir and voxilaprevir, as other registers publish it.
- IcelandVoseviGilead Sciences Ireland UC*
- PolandVoseviGilead Sciences Ireland UC
- United StatesVoseviGilead Sciences, Inc.
- IcelandVoseviGilead Sciences Ireland UC*
- FinlandVoseviGilead Sciences Ireland UC
- DenmarkVoseviGilead Sciences Ireland UC
- FinlandVoseviGilead Sciences Ireland UC
- DenmarkVoseviGilead Sciences Ireland UC
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ec9400c3-813a-425a-8a83-6537b4b38aab GET /v1/drugs/ec9400c3-813a-425a-8a83-6537b4b38aab?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Vosevi 400 mg - 100 mg - 100 mg",
"name_fr": "Vosevi 400 mg - 100 mg - 100 mg",
"name_nl": "Vosevi 400 mg - 100 mg - 100 mg",
"amp_code": "SAM516577-00",
"strengths": [
"100.0000",
"100.0000",
"400.0000",
"111.0000"
],
"pack_count": 2,
"substances": [
"Velpatasvir",
"Voxilaprevir",
"Sofosbuvir",
"Lactose"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Sofosbuvir, Velpatasvir and Voxilaprevir",
"authorisation_numbers": [
"EU/1/17/1223/001"
]
}See everything about sofosbuvir, velpatasvir and voxilaprevir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.